Prellis Biologics and start - up Volumetric Bio continue to commercialise their bioprinting projects . San Francisco - based Prellis , which raised $ 500 m in funding in July , aims to market its 3D - printed vascular scaffolds , as well as vascularised vascular devices and a vascular shunt for dialysis devices made from their own tissue . Meanwhile , Volumetric was launched to showcase the bioprinters , tools and technologies supporting research into vascular networks .
Prellis Biologics and start-up Volumetric Bio plan to commercialise their bioprinting projects. San Francisco-based Prellis, which raised $8.7m in funding in July, aims to market its 3D-printed vascular scaffolds, as well as vascularised skin grafts and a vascular shunt for dialysis patients made from their own tissue. Meanwhile, Volumetric was launched to commercialise the bioprinters, materials and reagents supporting research into vascular networks.